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A total of 3173 dyslipidemic patients treated with LLA and
managed by general practitioners were randomly selected from
a French GPs computerized database. History of CHD and
number of CRF (age, family history of premature CHD,
smoking, hypertension, HDL-C < 0.9mmol/L, diabetes) were
documented. Percent of patients above AFSSAPS TIL and NCEP
goal was deﬁned for each level of CHD risk. RESULTS: Twenty-
one percent of patients had a history of CHD. Using AFSSAPS
guidelines the distribution of primary prevention patients
according to the number of CRFs (1, 2, 3, >3) was 1.6, 25.5,
31.7, and 20.1%, respectively. Almost 40% of CHD patients
remained above TIL and the percentages of primary prevention
patients above TIL varied from 3.9% for patients with 1 CRF
to 46.5% for patients with > 3 CRFs (p < 0.001). Using NCEP
guidelines, percentage of patients not at goal in the different
CHD risk categories were signiﬁcantly higher and 74.3% of
CHD patients were not at LDL-C treatment goal. CONCLU-
SION: Seventy-three percent of patients prescribed LLA were at
high CHD risk. Increasing with CHD risk level, large numbers
of patients were above TIL and LDL-C treatment goal. More
effective interventions are needed in lipid lowering therapy. *
AFSSAPS: French Drug Agency.
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OBJECTIVES: To examine the relationship between Interna-
tional Normalized Ratio (INR) and outcomes (major bleeding
events and strokes) in atrial ﬁbrillation (AF) patients on antico-
agulation with warfarin. METHODS: A systematic review and
meta-analysis of studies published in English between January 1,
1985 and October 30, 2002 was performed. MEDLINE
(PubMed), Current Contents, and relevant reference lists were
searched. Studies enrolling patients with nonvalvular AF on war-
farin anticoagulation were eligible for inclusion if they reported
stroke and/or major bleeding events in relation to INR, or time
spent in therapeutic range. The risk of bleeds in overanticoagu-
lated patients (INR > 3) and the risk of strokes in underantico-
agulated patients (INR < 2) was assessed. RESULTS: Twenty-one
studies (6,248 patients) met all inclusion criteria. Of the 21
studies, target conventional INR of 2 to 3 was used in 9. An INR
< 2, compared with an INR > 2, was associated with an odds
ratio (OR) for ischemic events of 5.07 (95% conﬁdence interval
(CI) = 2.92, 8.80). An INR > 3, compared with an INR < 3, was
associated with an OR for bleeding events of 3.21 (95% CI =
1.24, 8.28). On average, in the four studies with a target INR
range of 2 to 3, AF patients on warfarin spent 61% of time
within, 13% of time above and 26% below the therapeutic
range. CONCLUSION: Available evidence indicates that in
patients with non-valvular AF, the risk of ischemic stroke with
insufﬁcient warfarin anticoagulation (INR < 2), and the risk of
bleeding events with overanticoagulation (INR > 3) is signiﬁ-
cantly higher relative to AF patients maintained within the rec-
ommended INR of 2 to 3. However, the data are sparse,
heterogeneous, and mostly based on clinical trials. More studies
evaluating clinical outcomes in relation to INR are needed, espe-
cially in a real-world setting.
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OBJECTIVE: Evaluate treatment of hyperlipidemia in Latin
America and determine factors associated with NCEP-III LDL-
C goal attainment in Coronary Heart Disease (CHD)/CHD risk
equivalent (< = 100mg/dl) and non-CHD patients with 2+ risk
factor (< = 130mg/dl). METHODS: Retrospective observational
study at 40 randomly selected specialists and 20 general prac-
tices (GP) centers in Mexico, Brazil and Colombia. Physicians
randomly selected adult (age > = 18) patients prescribed lipid
lowering drug (LLD) for minimum 12 weeks. Date of ﬁrst LLD
was the index date; follow-up cholesterol measures and LLD pre-
scribed were evaluated for minimum 3 months after index date.
RESULTS: Three-hundred sixty patients were studied, 25% from
GP and 75% from specialist centers; 45% had CHD/CHD equiv-
alent, and 35% had 2+ risk factors. Mean age was 57yrs (SD
12) and 53% were male. Median LDL-C reduction required to
attain NCEP-III goal at baseline was 48% for CHD and 23%
for non-CHD patients. There was no signiﬁcant difference in
LDL-C reduction required at baseline among the three countries.
Initial LLD for CHD group were 27% low dose statins (sim-
vastatin 10mg or equipotent), 36% medium dose statins 
(simvastatin 20mg or equipotent) and 18% high dose statins
(simvastatin 40mg or equipotent). Proportion of physicians 
prescribing high dose statins was higher (p < 0.05) in Brazil
(26%) than Mexico (16%) and Colombia (15%). Overall 45%
patients treated with statins alone attained LDL-C goals; 
only 28% of CHD group. After controlling for age, gender,
country, initial LLD, titration and comorbidities, patients with
baseline LDL-C > = 190mg/dl (OR = 0.47; 95% CI 0.30–0.74),
hypertension (OR = 0.58; 95% CI 0.37–0.92) and CHD (OR =
0.38; 95% CI 0.24–0.60) were least likely to achieve LDL-C
goal. CONCLUSION: Hyperlipidemic patients in some Lati-
namerican countries are generally treated with statins alone;
majority (55%) of patients failed to reach recommended NCEP-
III LDL-C goals.
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OBJECTIVES: Clinical trials demonstrated that low-density
lipoprotein (LDL) lowering therapy reduces mortality and mor-
bidity in coronary heart disease patients. Therefore, it is impor-
tant to ensure patient adhering to their LDL-lowering therapies.
In July 2001, an intensive treatment protocol was introduced at
the United Christian Hospital (UCH) in Hong Kong. The
purpose of this study is to describe the impact of the protocol
on the lipid levels in patients having elective percutaneous coro-
nary interventions (PCI). METHODS: Case notes were reviewed
retrospectively. The study cohort consisted of patients who were
above 18 years old requiring ﬁrst elective PCI from 1 July 2000
to 30 June 2002. Patients with a history of previous PCI or 
coronary artery bypass surgery were excluded. The intensive
